Pennant Group (PNTG) grants 26,000 stock options to Chief Clinical Officer

Rhea-AI Filing Summary

Pennant Group, Inc. reported a Form 4 showing its Chief Clinical Officer, Jason Paul Steik, received a grant of stock options for 26,000 shares of common stock at an exercise price of $33.30 per share. These options vest in five equal annual installments beginning on March 5, 2027, and represent his full reported option holdings of 26,000 shares following this award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Steik Jason Paul

(Last) (First) (Middle)

1675 E. RIVERSIDE DR

SUITE 150

(Street)

EAGLE ID 83616

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pennant Group, Inc. [ PNTG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Clinical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$33.3	03/05/2026		A		26,000(1)		03/05/2027	03/05/2036	Common Stock	26,000	$33.3	26,000	D

Explanation of Responses:

1. These shares vest in five equal annual installments beginning March 5, 2027.

Remarks:

The Form 4 is being filed late due to inadvertent administrative error.

	/s/ Kirk Cheney, as attorney in fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pennant Group (PNTG) report for Jason Paul Steik?

Pennant Group reported that Chief Clinical Officer Jason Paul Steik received a grant of 26,000 stock options. The options relate to common stock and were awarded as a compensation grant, not an open-market purchase, according to the Form 4 filing and its transaction code description.

What is the exercise price of the new Pennant Group (PNTG) stock options?

The granted stock options have an exercise price of $33.30 per share. This means Steik must pay $33.30 for each share if he exercises the options, according to the Form 4 disclosure for the 26,000-option award.

How do the Pennant Group (PNTG) options granted to Jason Steik vest?

The 26,000 stock options granted to Jason Steik vest in five equal annual installments. Vesting begins on March 5, 2027, as stated in the footnote, meaning one-fifth of the options becomes exercisable each year over the five-year schedule.

Is the Pennant Group (PNTG) Form 4 transaction an insider purchase or a grant?

The transaction is a grant of stock options, not an open-market purchase. The Form 4 uses transaction code “A” and describes it as a grant, award, or other acquisition, classifying it as compensation-related rather than a discretionary market buy.

How many Pennant Group (PNTG) options does Jason Steik hold after this grant?

Following the reported transaction, Jason Steik holds 26,000 stock options directly. The Form 4 shows total derivative securities following the transaction equal the 26,000 options granted, indicating this award accounts for his reported option position in the filing.